JCR Pharmaceuticals (4552) Stock Overview
Engages in the research, development, manufacture, import and export, and sale of pharmaceutical products, regenerative medicines, and drug substances in Japan. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 3/6 |
| Past Performance | 1/6 |
| Financial Health | 2/6 |
| Dividends | 4/6 |
Rewards
Risk Analysis
4552 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
JCR Pharmaceuticals Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥466.00 |
| 52 Week High | JP¥824.00 |
| 52 Week Low | JP¥445.00 |
| Beta | 0.13 |
| 1 Month Change | -14.96% |
| 3 Month Change | -25.20% |
| 1 Year Change | -18.25% |
| 3 Year Change | -66.00% |
| 5 Year Change | -86.65% |
| Change since IPO | 109.44% |
Recent News & Updates
Recent updates
Shareholder Returns
| 4552 | JP Pharmaceuticals | JP Market | |
|---|---|---|---|
| 7D | -6.2% | -5.7% | -0.2% |
| 1Y | -18.2% | 8.8% | 42.7% |
Return vs Industry: 4552 underperformed the JP Pharmaceuticals industry which returned 8.8% over the past year.
Return vs Market: 4552 underperformed the JP Market which returned 42.7% over the past year.
Price Volatility
| 4552 volatility | |
|---|---|
| 4552 Average Weekly Movement | 5.8% |
| Pharmaceuticals Industry Average Movement | 5.9% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in JP Market | 9.3% |
| 10% least volatile stocks in JP Market | 2.4% |
Stable Share Price: 4552 has not had significant price volatility in the past 3 months compared to the JP market.
Volatility Over Time: 4552's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1975 | 987 | Hiroyuki Sonoda | www.jcrpharm.co.jp |
JCR Pharmaceuticals Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, import and export, and sale of pharmaceutical products, regenerative medicines, and drug substances in Japan. It offers various therapeutic products, including GROWJECT used for the treatment of growth hormone deficiency and short stature; IZCARGO to treat Mucopolysaccharidosis type II; Agalsidase Beta BS I.V. Infusion used for the treatment of Fabry disease; and TEMCELL HS Inj used to treat acute graft-versus-host disease.
JCR Pharmaceuticals Co., Ltd. Fundamentals Summary
| 4552 fundamental statistics | |
|---|---|
| Market cap | JP¥56.85b |
| Earnings (TTM) | JP¥2.18b |
| Revenue (TTM) | JP¥40.32b |
Is 4552 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4552 income statement (TTM) | |
|---|---|
| Revenue | JP¥40.32b |
| Cost of Revenue | JP¥10.13b |
| Gross Profit | JP¥30.19b |
| Other Expenses | JP¥28.01b |
| Earnings | JP¥2.18b |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 17.85 |
| Gross Margin | 74.87% |
| Net Profit Margin | 5.40% |
| Debt/Equity Ratio | 113.8% |
How did 4552 perform over the long term?
See historical performance and comparisonDividends
Does 4552 pay a reliable dividends?
See 4552 dividend history and benchmarks| JCR Pharmaceuticals dividend dates | |
|---|---|
| Ex Dividend Date | Mar 30 2026 |
| Dividend Pay Date | Jun 24 2026 |
| Days until Ex dividend | 69 days |
| Days until Dividend pay date | 17 days |
Does 4552 pay a reliable dividends?
See 4552 dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/06 06:50 |
| End of Day Share Price | 2026/06/05 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2026/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
JCR Pharmaceuticals Co., Ltd. is covered by 15 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Tatsuyuki Arai | BofA Global Research |
| Hidemaru Yamaguchi | Citigroup Inc |
| Kazuaki Hashiguchi | Daiwa Securities Co. Ltd. |